Clinical trial
Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA…
NCT00113035 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00113035 |
|---|---|
| Title | Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease |
| Official title | Screening Protocol to Evaluate Acid Alpha Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease for Potential Inclusion in Future Clinical Studies With Myozyme (Alglucosidase Alfa) |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Pompe Disease |
| Enrollment | 60 |
| Start date | May 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jun 6, 2005 |
| Last update posted | May 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: